drugset / Trial / NCT01564199

Phase I Pharmacokinetic Study (SALBLOCK)

NCT01564199

Phase 1 Completed 20 enrolled Orion Corporation, Orion Pharma
RandomizedCrossoverOpen-labelTreatment

Summary

The objective of the study is to assess the extent to which the charcoal prevents the absorption of salmeterol and fluticasone via the GI tract. The assessment will be based on comparing the pharmacokinetic parameter area under the concentration-time curve (AUCt).

Timeline

Start
2012-04
Primary completion
2012-06
Completion
2012-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluticasone propionate Other / unclassified 1000 ug Oral
Subject Salmeterol Other / unclassified 100 ug Oral

Indications

No indication recorded.